Table 4 Detailed information of the top 10 sensitivity drugs in high-risk groups

Rapamycin

Drugs that selectively target mTORC1 are expected to impair cancer metabolism and are considered promising anti-cancer therapies

MTORC1

PI3K/MTOR signaling

PD.0325901

Mirdametinib (PD-0325901) is an oral, non-ATP-competitive, highly selective, and potent small-molecule inhibitor of MEK1 and MEK2

MEK1, MEK2

ERK MAPK signaling

Dasatinib

Dasatinib is an orally available short-acting dual ABL/SRC tyrosine kinase inhibitor (TKI). It potently inhibits BCR-ABL and SRC family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-a and PDGFR-b, and ephrin receptor kinase

ABL, SRC, Ephrins, PDGFR, KIT

RTK signaling, kinases

MG-132

The peptide-aldehyde proteasome inhibitor MG132 (carbobenzoxyl-l-leucyl-l-leucyl-l-leucine) induces the apoptosis of cells by a different intermediary pathway. Although the pathway of induction of apoptosis is different, it plays a crucial role in anti-tumor treatment

Proteasome, CAPN1

Protein stability and degradation

Cytarabine

Cytarabine (molecular formula: C9H13N3O5) interferes with DNA synthesis, acting on DNA/RNA polymerase (and other nucleotide reductase enzymes), reducing cell ability to replicate

Antimetabolite

Other

A-443654

A-443654, a specific Akt inhibitor, interferes with mitotic progression and bipolar spindle formation. A-443654 induces G2/M accumulation, defects in centrosome separation, and formation of either monopolar arrays or disorganized spindles

AKT1, AKT2, AKT3

PI3K/MTOR signaling

AZ628

AZ628 is a hydrophobic Raf-kinase inhibitor currently in clinical trial of various cancer

BRAF

ERK MAPK signaling

WH-4–023

WH-4-023 is a LCK inhibitors

SRC, LCK

Other, kinases

Mitomycin.C

Mitomycin C (MMC) is an alkylating agent with extraordinary ability to crosslink DNA, preventing DNA synthesis

DNA crosslinker

DNA replication

TW.37

TW-37 is a novel, potent and non-peptide Bcl-2 small-molecule inhibitor

BCL2, BCL-XL, MCL1

Apoptosis regulation